Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).

  • FEAnalytics.com
  • FEInvest.net
  • FETransmission.com
  • Investegate.co.uk
  • Trustnet.hk
  • Trustnetoffshore.com
  • Trustnetmiddleeast.com

For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.

WHAT INFORMATION DO WE COLLECT ABOUT YOU?

We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.

COOKIES

In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.

HOW WE USE INFORMATION

We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.

ACCESS TO YOUR INFORMATION AND CORRECTION

We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.

WHERE WE STORE YOUR PERSONAL DATA

The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.

CHANGES TO OUR PRIVACY POLICY

Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.

OTHER WEBSITES

Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.

CONTACT

If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Company Name matching 'Active Biotech'

Date
Time Source
Company
Announcement
07 Dec 2017 6:00 pm GNW     Active Biotech Active Biotech provides updated information abo...
01 Dec 2017 12:00 pm GNW     Active Biotech Active Biotech announce results in ARPEGGIO Pha...
17 Nov 2017 7:30 am GNW     Active Biotech Active Biotech's election committee appointed
09 Nov 2017 7:30 am GNW     Active Biotech Active Biotech AB - Interim report January - Se...
19 Oct 2017 1:00 pm GNW     Active Biotech Active Biotech's partner Teva presents new data...
10 Aug 2017 7:30 am GNW     Active Biotech Active Biotech AB - Interim report January - Ju...
19 Jun 2017 2:30 pm GNW     Active Biotech Helén Tuvesson new CEO of Active Biotech A...
16 Jun 2017 7:30 am GNW     Active Biotech Annual General Meeting of Active Biotech AB
17 May 2017 7:30 am GNW     Active Biotech Active Biotech: Notice of Annual General Meetin...
27 Apr 2017 7:30 am GNW     Active Biotech Active Biotech: Interim report January - March ...
12 Apr 2017 12:30 pm GNW     Active Biotech Active Biotech: FDA grants Orphan Drug Designat...
16 Feb 2017 7:30 am GNW     Active Biotech Active Biotech AB Year-end report January - Dec...
09 Jan 2017 12:00 pm GNW     Active Biotech The European Patent Office grants patent for ta...
30 Dec 2016 7:30 am GNW     Active Biotech Number of shares and votes in Active Biotech
12 Dec 2016 4:31 pm GNW     Active Biotech Active Biotech's rights issue completed
22 Nov 2016 2:05 pm GNW     Active Biotech Active Biotech's election committee appointed
18 Nov 2016 2:15 pm GNW     Active Biotech Prospectus relating to Active Biotech's rights ...
11 Nov 2016 6:01 pm GNW     Active Biotech Active Biotech carries out rights issue of appr...
  6:00 pm GNW     Active Biotech Active Biotech AB Interim report January - Sept...
26 Oct 2016 7:31 am GNW     Active Biotech Active Biotech and NeoTX enter into a partnersh...
  7:25 am GNW     Active Biotech Active Biotech postpone publication of the inte...
19 Sep 2016 7:30 am GNW     Active Biotech Active Biotech update on laquinimod Development...
25 Jun 2015 1:01 pm GNW     Active Biotech Teva and Active Biotech Announce Completion of ...
12 Jun 2015 7:30 am GNW     Active Biotech Annual General Meeting of Active Biotech AB
01 Jun 2015 9:01 am GNW     Active Biotech Active Biotech focuses the operations on the la...
12 May 2015 7:30 am GNW     Active Biotech Notice of Annual General Meeting of Shareholders
30 Apr 2015 9:01 am GNW     Active Biotech Annual Report 2014 Active Biotech AB (publ)
23 Apr 2015 7:00 pm GNW     Active Biotech Teva and Active Biotech Announce First Patient ...
  7:31 am GNW     Active Biotech Active Biotech AB Interim report January - Marc...
16 Apr 2015 6:02 am GNW     Active Biotech Active Biotech and Ipsen announce their decisio...
11 Feb 2015 7:30 am GNW     Active Biotech Active Biotech AB Year-end report January - Dec...
30 Jan 2015 7:30 am GNW     Active Biotech Number of shares and votes in Active Biotech
12 Jan 2015 7:30 am GNW     Active Biotech Active Biotech to Present at the 33rd Annual J....
29 Dec 2014 2:30 pm GNW     Active Biotech Active Biotech's rights issue of approximately ...
09 Dec 2014 7:30 am GNW     Active Biotech Active Biotech's election committee appointed
05 Dec 2014 7:30 am GNW     Active Biotech Prospectus relating to Active Biotech's rights ...
01 Dec 2014 5:15 pm GNW     Active Biotech Extraordinary General Meeting of Active Biotech...
05 Nov 2014 7:32 am GNW     Active Biotech Active Biotech AB: Notice of Extraordinary Gene...
  7:31 am GNW     Active Biotech Active Biotech strengthens its financial positi...
  7:30 am GNW     Active Biotech Active Biotech AB Interim report January - Sept...
04 Nov 2014 1:00 pm GNW     Active Biotech Teva and Active Biotech Announce Expansion of L...
12 Sep 2014 1:00 pm GNW     Active Biotech Teva Presents New Clinical Safety Data in RRMS ...
14 Aug 2014 7:31 am GNW     Active Biotech Active Biotech's partner Teva initiates a laqui...
07 Aug 2014 7:30 am GNW     Active Biotech Active Biotech AB Interim report January-June 2014
11 Jun 2014 7:30 am GNW     Active Biotech Active Biotech presents data on paquinimod at E...
03 Jun 2014 7:30 am GNW     Active Biotech Active Biotech to Present at Jefferies 2014 Hea...
23 May 2014 7:30 am GNW     Active Biotech Teva and Active Biotech to continue with the de...
16 May 2014 7:30 am GNW     Active Biotech Annual General Meeting of Active Biotech AB
24 Apr 2014 7:30 am GNW     Active Biotech Active Biotech AB Interim report January - Marc...
14 Apr 2014 7:30 am GNW     Active Biotech Active Biotech - Notice of Annual General Meeti...
07 Apr 2014 9:01 am GNW     Active Biotech Annual Report 2013 Active Biotech AB (publ)
19 Feb 2014 1:01 pm GNW     Active Biotech Change in the clinical development program for ...
13 Feb 2014 7:31 am GNW     Active Biotech Active Biotech AB Year-end report January - Dec...
24 Jan 2014 12:13 pm GNW     Active Biotech Teva and Active Biotech Remain Committed to the...
09 Jan 2014 10:19 am GNW     Active Biotech Active Biotech to Present at the 32nd Annual J....
20 Dec 2013 12:25 pm GNW     Active Biotech Laquinimod CHMP/EMA Opinion
14 Nov 2013 7:30 am GNW     Active Biotech Active Biotech to Present at the Jefferies 2013...
11 Nov 2013 7:31 am GNW     Active Biotech Active Biotech's election committee appointed
07 Nov 2013 7:30 am GNW     Active Biotech Active Biotech AB Interim Report January - Sept...
04 Nov 2013 7:31 am GNW     Active Biotech Active Biotech's partner Teva initiates a furth...


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t